ストックスクリーナーアプリを入手
23.60
2.61%
0.60
前日終値:
$23.00
開ける：
$22.84
24時間の取引高:
3.64M
Relative Volume:
1.90
時価総額：
$2.28B
収益：
$610.16M
当期純損益:
$-532.93M
株価収益率:
-4.2686
EPS:
-5.5287
ネットキャッシュフロー:
$-442.30M
1週間 パフォーマンス:
-30.97%
1か月 パフォーマンス:
-29.49%
6か月 パフォーマンス:
-40.19%
1年 パフォーマンス:
-42.65%
1日の値動き範囲:
$22.50
$24.00
1週間の範囲:
$18.41
$24.00
52週間の値動き範囲:
$18.41
$46.50
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
RARE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
23.60 | 2.22B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide - Benzinga
Levi & Korsinsky Investigates Possible Securities Fraud by Ultragenyx Pharmaceutical Inc. (RARE) - ACCESS Newswire
Ultragenyx Phase III Data Reveal Limits of Bone Density Endpoints in Rare Bone Disease - BioPharm International
Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Pharmaceutical (RARE): B of A Securities Lowers Price Target | RARE Stock News - GuruFocus
Ultragenyx completes rolling submission of BLA for DTX401 - The Pharma Letter
Ultragenyx Pharmaceuticals Loses $1 Billion in Market Value After Bone Drug Fails Phase III Trials - geneonline.com
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials By Investing.com - Investing.com South Africa
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures - BioSpace
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
BofA Securities lowers Ultragenyx Pharma stock price target on failed trials - Investing.com
Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials - Fierce Biotech
Analysts Are Bullish on Top Healthcare Stocks: Tectonic Therapeutic (TECX), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials - Indian Pharma Post
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy - The Globe and Mail
Lacklustre Performance Is Driving Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 32% Price Drop - 富途牛牛
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN
Ultragenyx (RARE) Completes U.S. Application for Gene Therapy DT - GuruFocus
Ultragenyx completes rolling FDA submission for US approval of gene therapy - Seeking Alpha
Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus - ts2.tech
Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last? - Nasdaq
Ultragenyx (RARE) Rockets 15.5% on Bargain-Hunting After Steep Fall - Finviz
Ultragenyx (RARE) rockets 15.5% on bargain-hunting after steep fall - MSN
Why Ultragenyx Pharmaceuticals stock is plummeting today - MSN
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Why Did RARE Stock Plunge Over 41% Today? - Stocktwits
Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx completes BLA submission for GSDIa gene therapy By Investing.com - Investing.com Nigeria
Why Ultragenyx Pharmaceutical stock is bouncing back today - MSN
Ultragenyx Completes Rolling Submission of Biologics License Application for DTX401 Gene Therapy - marketscreener.com
Ultragenyx completes BLA filing for GSDIa gene therapy - TipRanks
Ultragenyx (RARE) Completes Key FDA Submission for Gene Therapy Approval - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx completes BLA submission for GSDIa gene therapy - Investing.com
Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE) - MarketBeat
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - The Globe and Mail
Ultragenyx Pharmaceutical Inc. Completes Rolling Submission of BLA for DTX401 Gene Therapy to Treat Glycogen Storage Disease Type Ia - Quiver Quantitative
Ultragenyx Pharmaceutical Completes BLA Submission for DTX401 - TradingView — Track All Markets
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today - AOL.com
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for ... - Caledonian Record
New gene therapy cut cornstarch use in rare GSDIa disease trial - Stock Titan
Ultragenyx SVP Huizenga sells $2922 in shares By Investing.com - Investing.com Nigeria
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Ultragenyx SVP Huizenga sells $2922 in shares - Investing.com
Ultragenyx (RARE) Sees Potential Rebound Despite Recent Setback - GuruFocus
Leerink Partners Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $70.00 - MarketBeat
RARE: Baird Lowers Price Target to $47 on Outperform Rating | RA - GuruFocus
Ultragenyx (RARE) Shares Surge with Nearly 10% Increase - GuruFocus
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
Ultragenyx Pharmaceutical Inc (RARE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Dec 29 '25 |
Sale |
34.38 |
85 |
2,922 |
50,450 |
| Horn Howard | Chief Financial Officer |
Dec 10 '25 |
Sale |
36.38 |
3,081 |
112,087 |
95,146 |
0.57%
大文字化:
|
ボリューム (24 時間):